Targeting mTOR for Immunity to Cancer

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Abstract

DESCRIPTION (provided by applicant): Cancer affects people of all ages, but the risk of developing most forms of this disease increases with age. How the immune system changes with age and the effect that this has on the development or control of cancer is not completely clear. However we do know that, in general, CD8 T cells play a crucial role in immunity to cancer. Upon activation, CD8 T cells undergo a predictable developmental program characterized by distinct phases encompassing first the expansion, and then contraction, of Ag-specific effector (TE) populations, followed by the persistence of long-lived memory cells (TM). Since long-lived CD8 TM cells mediate protective immunity to the re-establishment of cancer, the mechanisms underlying the generation and maintenance of these cells remain a highly desirable target for clinical intervention. Our previous work has revealed that the promotion of mitochondrial fatty acid oxidation (FAO), a pathway of lipid catabolism that fuels the TCA cycle, in CD8 T cells during an immune response is crucial to their development into long-lived TM cells. We found that the mammalian target of rapamycin (mTOR) plays a central role in this process and exploited this finding to enhance CD8 TM development after vaccination. This proposal extends our novel concept that cellular metabolism regulates the development of CD8 TM and that the mTOR pathway modulates this process. Based on our observations, and a panel of supportive preliminary data, we hypothesize that 1) inhibitors of mTOR promote the development of CD8 TM cells that protect against cancer, and 2) mTOR controls this process by regulating metabolism in these cells. The long-term goal of these studies is to facilitate the development of immunotherapies against cancer.